Microwave ablation for papillary thyroid microcarcinoma monitored with contrast-enhanced ultrasound and genetic testing

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational study in which adults with a single low-risk papillary thyroid microcarcinoma (≤1 cm) who have undergone fine-needle aspiration and an 88-gene panel may choose microwave ablation or surgical resection. Treatment effects and prognosis will be followed using contrast-enhanced ultrasound combined with molecular diagnostic data. The study will track local tumor control, complications, thyroid function, and lesion changes over time. Data will be collected at Sun Yat-sen Memorial Hospital to compare outcomes and identify molecular markers linked to prognosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18-70 years, gender not specified;
* Patients with low-risk PTMC receiving initial treatment (meeting all the following conditions: single lesion with a maximum diameter ≤1cm; no cervical lymph node metastasis; no distant metastasis; no extrathyroidal extension; no family history of thyroid cancer; no history of head and neck radiation during childhood);
* Patients who have undergone fine-needle aspiration cytology examination of thyroid nodules and 88-gene panel testing for thyroid cancer before surgery;
* Patients voluntarily choose to undergo microwave ablation therapy or surgical resection.

Exclusion Criteria:

* Tumor located in the isthmus of the thyroid;
* Pathological high-risk subtypes (tall cell subtype, columnar cell subtype, diffuse sclerosing subtype, solid/insular subtype, oncocytic subtype);
* Progressive enlargement of the cancer lesion in the short term (increase of more than 3mm within 6 months);
* Pregnant women, lactating women;
* Patients with severe coagulation disorders;
* Patients with contralateral vocal cord dysfunction;
* Patients with contraindications to ultrasound contrast agents;
* Other conditions deemed ineligible for enrollment by the investigator.

Where it's running

• Sun Yat-sen Memorial Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Ou, Dr.
• Email: ouqy5@mail.sysu.edu.cn
• Phone: 020-34071020

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• International effort to set liver CEUS image-quality standards and a rating tool

  A group of experts is testing a standardized set of quality criteria and a rating tool to judge liver CEUS images.

  Recruiting University of Bern · Bern, Canton of Bern · NCT07656181

• EUS-Guided Ablation for Pancreatic and GI Lesions Registry

  This registry collects real-world data on adults undergoing EUS-guided RFA or MWA to treat pancreatic or other GI lesions during routine care to see how these treatments affect lesion size, survival, and symptoms.

  Recruiting West Virginia University · Morgantown, West Virginia · NCT07625189

• Contrast ultrasound imaging of uterine spiral arteries after delivery

  We will try using contrast-enhanced ultrasound after delivery to visualize small uterine spiral arteries and measure uterine artery blood flow in people with a single pregnancy at term who deliver at Máxima Medical Center.

  Recruiting Maxima Medical Center · Veldhoven · NCT07422181

• Using contrast-enhanced ultrasound to predict lymph node spread in small papillary thyroid cancer

  This will test whether contrast-enhanced ultrasound can predict lymph node spread before surgery in people with small (T1N0M0) papillary thyroid cancer.

  Recruiting at 2 sites Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangdong, Guangzhou and 1 other locations · NCT07357571

• Contrast-enhanced ultrasound to track how PRRT works in gastroenteropancreatic neuroendocrine tumors

  This tests whether contrast-enhanced ultrasound can show treatment response to peptide receptor radionuclide therapy (PRRT) in adults with unresectable somatostatin-receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP‑NETs).

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, Rome · NCT07319416

• AI-guided ultrasound and MRI staging to guide bladder cancer treatment

  This project will test whether a deep-learning system using ultrasound, MRI, and pathology can more accurately stage bladder cancer and predict who will benefit from additional chemotherapy for patients with suspected bladder tumors.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07051083

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.